Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
381-400 of 998 trials

Advanced Gastric Cancer: AZD0901 Treatment Study

We are studying how well AZD0901 works and its safety compared to standard treatments for adults with advanced gastric or gastroesophageal junction cancer that has high levels of a protein called CLDN18.2.

Advanced Gastric CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Urothelial Cancer: Sacituzumab Govitecan Study

We are investigating a new treatment for patients with advanced urothelial cancer that cannot be removed by surgery. The study aims to see how effective and safe this treatment is compared to existing options.

Urothelial Cancer of the Renal Pelvis>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineOncologyUrology

Ulcerative Colitis: GS-1427 Study

We are testing a new medication, GS-1427, for adults with moderately to severely active ulcerative colitis. The study aims to see if it can improve symptoms and achieve remission compared to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Liver Tumors: Indocyanine Green for Better Detection

We are testing whether a dye can help surgeons find liver tumors more easily during surgery. This study aims to improve surgical outcomes and understand how the dye behaves in the liver.

Resectable Malignant Liver Tumor>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHepatologyOncology

Metastatic Pancreatic Adenocarcinoma: TTX-030 and Chemotherapy

We are studying if adding TTX-030 and possibly budigalimab to standard chemotherapy helps patients with untreated metastatic pancreatic cancer. This trial aims to evaluate the effectiveness and safety of these combinations.

Metastatic Pancreatic Cancer1-2 yearsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

Meningioma Treatment: Everolimus and 177Lu-DOTATATE

We are studying a new combination treatment for patients with grades 2 and 3 refractory meningioma. The goal is to see if this approach can help improve survival and manage tumor growth.

Malignant Meningiomas1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyOncology

Whooping Cough Vaccine: Tdap-IPV Study

We are studying whether a booster shot of the Tdap-IPV vaccine helps prevent colonization by whooping cough bacteria in healthy adults after exposure. This research aims to improve vaccination strategies against whooping cough.

Whooping Cough≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious Diseases

Head and Neck Cancer: Amivantamab Treatment Study

We are studying the effects of amivantamab in patients with recurrent or metastatic head and neck squamous cell carcinoma. This trial looks at its use alone and with other standard treatments to see how well it works.

Recurrent Head and Neck CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Nipocalimab for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

We are studying whether nipocalimab can help adults with CIDP delay relapse and improve their symptoms compared to a placebo. This trial will also assess the safety of the treatment.

Chronic Inflammatory Demyelinating PolyneuropathyEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Neutropenia: Mavorixafor Study

We are investigating a new medication, mavorixafor, for people with neutropenia who have frequent infections. The study will assess how well it works and its safety compared to a placebo.

Neutropenia1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInfectious DiseasesInternal Medicine

Advanced Epithelial Ovarian Cancer: Radspherin® Treatment

We are studying whether Radspherin® can improve survival and quality of life for patients with advanced ovarian cancer and peritoneal metastasis. This trial focuses on those scheduled for chemotherapy and surgery.

Peritoneal Carcinomatosis>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Chondrosarcoma: Ivosidenib Treatment Study

We are studying the effects of ivosidenib in adults with locally advanced or metastatic chondrosarcoma. This trial aims to see if it improves tumor outcomes and overall survival compared to standard treatments.

Chondrosarcoma>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteOncology

Advanced Solid Tumors: D3S-001 Treatment Study

We are testing the safety and tolerability of D3S-001, alone or with other cancer medicines, for adults with advanced solid tumors that have a KRAS p.G12C mutation. This study aims to understand how the treatment works and its effects on tumors.

Advanced Solid Tumors with a KRAS p.G12C MutationSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Seasonal Allergic Rhinitis: PQ Grass Treatment for Kids

We are studying a new treatment for children and teens with seasonal allergic rhinitis caused by grass pollen. The goal is to see if it helps reduce symptoms and is safe for long-term use.

Allergic Rhinitis and Conjunctivitis>2 yearsConfirmation phase (III)>20 visitsStandard MedicinesCost ReimbursementPartially RemoteAllergologyPediatrics

PIK3CA-Related Overgrowth Spectrum: Alpelisib Study

We are investigating whether the medication alpelisib is safe and effective for individuals with PIK3CA-related overgrowth spectrum. This study includes both children and adults to assess its impact on their symptoms and overall health.

PIK3CA-Related Overgrowth Spectrum6-12 monthsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineOncology

Mechanical Heart Valves: Lower INR Study

We are evaluating if a lower INR range is safer and more effective for patients with bileaflet aortic mechanical valves. This may help reduce bleeding risks associated with current treatment methods.

Aortic Valve Replacement Treatment>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Ravulizumab for Children with NMOSD

We are studying the safety and effectiveness of Ravulizumab in children and adolescents with NMOSD. This trial aims to see how it affects their neurological function and overall quality of life.

Neuromyelitis Optica Spectrum Disorder1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Lupus Nephritis: Ianalumab Study

We are studying whether ianalumab can improve kidney function in people with active lupus nephritis compared to a placebo. This trial also looks at the safety and tolerability of the treatment.

Lupus Nephritis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNephrologyRheumatology

Neuroendocrine Tumors: Personalized vs. Standard RadioTherapy

We are comparing personalized radionuclide therapy with standard treatment for patients with neuroendocrine tumors. The goal is to see which approach is safer and more effective in shrinking tumors and improving quality of life.

Neuroendocrine Tumors6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Kidney Health in Type 2 Diabetes: Empagliflozin and Finerenone Study

We are exploring how well two medications work for kidney health in people with type 2 diabetes. This remote trial aims to personalize treatment based on individual responses.

Type 2 DiabetesAlbuminuria≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteDiabetologyInternal MedicineNephrology